vaccines

Despite continuous work by the scientific community, malaria remains one of the largest and deadliest diseases on the planet. The disease, which is spread via the bites of female Anopheles mosquitoes, was responsible for 627,000 deaths in 2020, with 95% of those occurring in Africa.    The disease largely affects at-risk groups such as infants, children […]

News round-up by DDW’s Reece Armstrong for 18-22 April    Covid-19, the link between ageing and genetic mutations, alongside funding opportunities for drug developers are some of the themes of this week’s news round-up.   1: Researchers shed light on ageing in new study   Animals with a large difference in lifespan and size end their natural lives […]

Specialist RNA process developer eTheRNA Manufacturing has introduced a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.  This new LNP service uses eTheRNA’s proprietary lipid libraries and formulations to facilitate targeted delivery and tailored biodistribution solutions. Through working with the company’s […]

Moderna has announced new results from in vitro neutralisation studies of sera from individuals vaccinated with the Moderna Covid-19 vaccine showing activity against variants of SARS-CoV-2. Vaccination with the Moderna Covid-19 vaccine produced neutralising titres against all variants tested, including additional versions of the Beta variant (B.1.351, first identified in South Africa), three lineage variants […]

Lu Rahman looks at the growing role of real world evidence and its benefits in the fight against Covid-19. Real world evidence (RWE)  is nothing new. While clinical trials have a significant part to play  – and indeed remain the ultimate standard for advancing new drugs to markets – gathering observational data from clinical settings […]

News round-up by DDW’s Megan Thomas for 28 June – 2 July This week in news The last year and a half has accelerated the virology scene at a pace that was previously unseen, and not exclusively for Covid-19. Vaccines continue to be an unquestionably important part of how we move through the world and […]

Johnson & Johnson has announced data that demonstrated its single-shot Covid-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. The […]

Two US Phase I clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs—an approach termed chemoprophylaxis vaccination. A Phase II clinical trial […]

Two doses of the Oxford-AstraZeneca Covid-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains. These laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre are published as a Research letter in […]

Sanofi will invest approximately €400 million annually in a vaccines mRNA Centre of Excellence. The centre will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams across sites at Cambridge, MA […]